Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors
Ravelo A, Patel A, To T, Li S, Huntington S. Real-World Healthcare Costs Among Patients With Chronic Lymphocytic Leukemia Receiving First-Line Treatment With Venetoclax + Obinutuzumab Versus Bruton Tyrosine Kinase Inhibitors. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s180. DOI: 10.1016/s2152-2650(24)00569-x.Peer-Reviewed Original Research